Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01199978 · ClinicalTrials.gov registry record · Phase 2
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
A Phase 2 study of Vestibular Schwannoma and Acoustic Neuroma, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01199978 is a Phase 2 study of Vestibular Schwannoma and Acoustic Neuroma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 48-participant average among 7 other Vestibular Schwannoma trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01199978, a Phase 2 study of Vestibular Schwannoma and Acoustic Neuroma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study we are looking at another type of radiation called proton radiation which is known to spare surrounding normal tissues from radiation. The proton radiation will be delivered using fractionated stereotactic radiotherapy (FSRT) to improve localization of the small tumor target. Proton radiation delivers minimal radiation beyond the area of the tumor. This may reduce side effects that patients would normally experience with conventional radiation therapy. In this research study, we are looking to determine the effects of fractionated proton radiotherapy on long-term hearing preservation and controlling tumor growth.
Conditions Studied
Interventions
- DRUG Losartan
- RADIATION Fractionated proton radiation
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-03-08 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01199978
The ClinicalTrials.gov registry entry for NCT01199978 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 48-participant average among 7 other Vestibular Schwannoma trials with a reported enrollment target (37% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Vestibular Schwannoma appearing as the primary indexed condition, and to 2 interventions - of which Losartan is the first listed.
NCT01199978 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01199978 about?
NCT01199978 is a clinical study titled "Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma". In this research study we are looking at another type of radiation called proton radiation which is known to spare surrounding normal tissues from radiation. The proton radiation will be delivered using fractionated stereotactic radiotherapy (FSRT) to improve localization of the small tumor target. ...
What is the current status of trial NCT01199978?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2011-03-08. Estimated completion is 2026-11.
What conditions does trial NCT01199978 study?
This clinical trial studies the following conditions: Vestibular Schwannoma, Acoustic Neuroma.
What interventions are being tested in trial NCT01199978?
The interventions under investigation include: Losartan (DRUG), Fractionated proton radiation (RADIATION).
Who is sponsoring clinical trial NCT01199978?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01199978 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vestibular Schwannoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Aspirin in Patients With Vestibular Schwannoma
ACTIVE NOT RECRUITING · Phase 2
-
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
COMPLETED · Phase 2
-
StableEyes With Active Neurofeedback
RECRUITING · NA
-
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
RECRUITING · Phase 1
-
CI Following VS Removal or Labyrinthectomy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.